Assessment of The Impact of Apremilast on Levels of IL-17, IL-23, and Lipids in Obese Psoriatic Patient

Background: Psoriasis is an immune-mediated inflammatory disease with unknown aetiology that may be associated with the defect in proliferation and differentiation of the keratinocytes related to inflammatory cell infiltration. According to published reports, it is universal in occurrence; its prev...

Full description

Saved in:
Bibliographic Details
Main Authors: Haitham M. Saad, Adil A. Noaimi, Halla Gh. Mahmood
Format: Article
Language:English
Published: College of Medicine University of Baghdad 2024-12-01
Series:مجلة كلية الطب
Subjects:
Online Access:https://iqjmc.uobaghdad.edu.iq/index.php/19JFacMedBaghdad36/article/view/2260
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832594676323975168
author Haitham M. Saad
Adil A. Noaimi
Halla Gh. Mahmood
author_facet Haitham M. Saad
Adil A. Noaimi
Halla Gh. Mahmood
author_sort Haitham M. Saad
collection DOAJ
description Background: Psoriasis is an immune-mediated inflammatory disease with unknown aetiology that may be associated with the defect in proliferation and differentiation of the keratinocytes related to inflammatory cell infiltration. According to published reports, it is universal in occurrence; its prevalence in different populations varies from 0.1% to 11.8%. Receiving Apremilast resulted in a strong reduction in interleukin 17 and interleukin 23, as well as reduced expression of other inflammatory cytokines and improvement of psoriatic lesions. Objectives: This study aimed to assess the impact of Apremilast on levels of IL-17, IL-23, and lipids in obese psoriatic patients. Methods: Thirty obese patients with psoriasis were included in this prospective interventional study to measure serum levels of lipid profile, IL-17, and IL-23, before and after receiving Apremilast treatment. A t-test was used to compare between means. Results: The mean age of the participants was 38 years. The most common age group was 30–40 years. The levels of IL-17 before the administration of Apremilast were 225.55 ± 7.70 pg/mL. After six months of treatment with Apremilast, a statistically significant reduction was seen, with the value decreasing to 183.41 ±2.33 pg/ml. IL-22 levels before the administration of Apremilast were measured to be 76.42 ± 4.03 pg/mL. After six months of treatment with Apremilast, these levels exhibited a non-significant decrease to 67.15 ± 5.40 pg/ml. Modest alterations were noted in the lipid profile. Conclusion: The use of Apremilast is effective in decreasing IL-17 levels, which have pro-inflammatory effects; this leads to improvement in psoriatic lesions. Moreover, receiving Apremilast in obese psoriatic individuals led to a reduction in TG levels and an elevation in HDL-C levels. Additionally, a rise in TC levels and LDL-C was seen.
format Article
id doaj-art-280f80b3b67e46d7b8c0e76ce3623eab
institution Kabale University
issn 0041-9419
2410-8057
language English
publishDate 2024-12-01
publisher College of Medicine University of Baghdad
record_format Article
series مجلة كلية الطب
spelling doaj-art-280f80b3b67e46d7b8c0e76ce3623eab2025-01-19T12:24:10ZengCollege of Medicine University of Baghdadمجلة كلية الطب0041-94192410-80572024-12-0166410.32007/jfacmedbaghdad.6642260Assessment of The Impact of Apremilast on Levels of IL-17, IL-23, and Lipids in Obese Psoriatic PatientHaitham M. Saad0https://orcid.org/0009-0003-3135-0281Adil A. Noaimi1https://orcid.org/0000-0002-2436-7988Halla Gh. Mahmood2https://orcid.org/0000-0002-7248-4409Al-Anbar Health Directorate, Ministry of Health, Anbar, Iraq.Department of Internal Medicine, College of Medicine, University of Baghdad, Baghdad, Iraq.Department of Clinical Biochemistry, College of Medicine, University of Baghdad, Baghdad, Iraq. Background: Psoriasis is an immune-mediated inflammatory disease with unknown aetiology that may be associated with the defect in proliferation and differentiation of the keratinocytes related to inflammatory cell infiltration. According to published reports, it is universal in occurrence; its prevalence in different populations varies from 0.1% to 11.8%. Receiving Apremilast resulted in a strong reduction in interleukin 17 and interleukin 23, as well as reduced expression of other inflammatory cytokines and improvement of psoriatic lesions. Objectives: This study aimed to assess the impact of Apremilast on levels of IL-17, IL-23, and lipids in obese psoriatic patients. Methods: Thirty obese patients with psoriasis were included in this prospective interventional study to measure serum levels of lipid profile, IL-17, and IL-23, before and after receiving Apremilast treatment. A t-test was used to compare between means. Results: The mean age of the participants was 38 years. The most common age group was 30–40 years. The levels of IL-17 before the administration of Apremilast were 225.55 ± 7.70 pg/mL. After six months of treatment with Apremilast, a statistically significant reduction was seen, with the value decreasing to 183.41 ±2.33 pg/ml. IL-22 levels before the administration of Apremilast were measured to be 76.42 ± 4.03 pg/mL. After six months of treatment with Apremilast, these levels exhibited a non-significant decrease to 67.15 ± 5.40 pg/ml. Modest alterations were noted in the lipid profile. Conclusion: The use of Apremilast is effective in decreasing IL-17 levels, which have pro-inflammatory effects; this leads to improvement in psoriatic lesions. Moreover, receiving Apremilast in obese psoriatic individuals led to a reduction in TG levels and an elevation in HDL-C levels. Additionally, a rise in TC levels and LDL-C was seen. https://iqjmc.uobaghdad.edu.iq/index.php/19JFacMedBaghdad36/article/view/2260ApremilastIL-17IL-23 ObesePsoriasis
spellingShingle Haitham M. Saad
Adil A. Noaimi
Halla Gh. Mahmood
Assessment of The Impact of Apremilast on Levels of IL-17, IL-23, and Lipids in Obese Psoriatic Patient
مجلة كلية الطب
Apremilast
IL-17
IL-23
Obese
Psoriasis
title Assessment of The Impact of Apremilast on Levels of IL-17, IL-23, and Lipids in Obese Psoriatic Patient
title_full Assessment of The Impact of Apremilast on Levels of IL-17, IL-23, and Lipids in Obese Psoriatic Patient
title_fullStr Assessment of The Impact of Apremilast on Levels of IL-17, IL-23, and Lipids in Obese Psoriatic Patient
title_full_unstemmed Assessment of The Impact of Apremilast on Levels of IL-17, IL-23, and Lipids in Obese Psoriatic Patient
title_short Assessment of The Impact of Apremilast on Levels of IL-17, IL-23, and Lipids in Obese Psoriatic Patient
title_sort assessment of the impact of apremilast on levels of il 17 il 23 and lipids in obese psoriatic patient
topic Apremilast
IL-17
IL-23
Obese
Psoriasis
url https://iqjmc.uobaghdad.edu.iq/index.php/19JFacMedBaghdad36/article/view/2260
work_keys_str_mv AT haithammsaad assessmentoftheimpactofapremilastonlevelsofil17il23andlipidsinobesepsoriaticpatient
AT adilanoaimi assessmentoftheimpactofapremilastonlevelsofil17il23andlipidsinobesepsoriaticpatient
AT hallaghmahmood assessmentoftheimpactofapremilastonlevelsofil17il23andlipidsinobesepsoriaticpatient